Загрузка страницы

Michael Mina - The neglected CT (Cycle Threshold) levels to determine viral load and infectiousness

Dr. Michael Mina, MD, PhD is an Assistant Professor of Epidemiology at Harvard T. H. Chan School of Public Health and a core member of the Center for Communicable Disease Dynamics (CCDD). He is additionally an Assistant Professor in Immunology and Infectious Diseases at HSPH and Associate Medical Director in Clinical Microbiology (molecular diagnostics) in the Department of Pathology at Brigham and Women’s Hospital, Harvard Medical School

He earned his MD and PhD degrees from Emory University, with doctoral work split between CDC, St. Jude Children’s Research Hospital, the Respiratory and Meningeal Pathogens Research Unit in Johannesburg, South Africa and the Emory Vaccine Center. He completed his post-doctoral work at Princeton University in Ecology and Evolutionary Biology (of infectious disease dynamics) with Prof. Bryan Grenfell and at Harvard Medical School in the Department of Genetics with Prof. Stephen Elledge. He completed his residency training in clinical pathology at Brigham and Women’s Hospital / Harvard Medical School.

Michael’s research combines mathematical and epidemiological models with high-throughput phage-display based serological laboratory investigations, including development of new technologies and statistical pipelines to better understand the population and immunological consequences and patterns underlying infectious diseases. Much of the work towards new technology development is performed in close collaboration with Steve Elledge at HMS. Major themes of his lab include (i) development of new approaches (laboratory and statistical methods) to enable extremely high-throughput serological surveillance of infectious pathogens; (ii) use of high-complexity antibody profiling and epidemiological data to understand the pathogenesis of vaccine preventable diseases, with a specific focus on measles infections and vaccines; (iii) elucidating broad unintended / heterologous effects of vaccines to alter transmission patterns of unrelated infectious pathogens – using serology and dynamical models; and (iv) understanding the life-history of infectious pathogens across ages, genders, geographies and times. In addition to his interests in infectious diseases, his research also explores more fundamental questions of immunity and immune repertoires: how they form, how they persist, how they are passed on and how they become perturbed during natural life-events.

Видео Michael Mina - The neglected CT (Cycle Threshold) levels to determine viral load and infectiousness канала Co-Immunity
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
4 сентября 2020 г. 1:51:50
00:08:25
Другие видео канала
Michael Mina - The problem of PCR sensitivity: False Infectious - False negatives as False positivesMichael Mina - The problem of PCR sensitivity: False Infectious - False negatives as False positivesCOVID 19 Antibody testing - What do I need to know?COVID 19 Antibody testing - What do I need to know?Michael Yeadon - “It is obvious to any biological expert that the pandemic is fundamentally over”Michael Yeadon - “It is obvious to any biological expert that the pandemic is fundamentally over”Michael Mina - Millions of people are being quarantined and contact traced for no reasonMichael Mina - Millions of people are being quarantined and contact traced for no reasonJohn Ioannidis - Overestimation. Risk Gradience. Wide Spread. Nosocomial Infection. Sweden. Life.John Ioannidis - Overestimation. Risk Gradience. Wide Spread. Nosocomial Infection. Sweden. Life.Michael Mina, MD, PhD - The Latest on COVID-19 Testing: How Do We Re-Open?Michael Mina, MD, PhD - The Latest on COVID-19 Testing: How Do We Re-Open?John Lee - Studies show that 40% to 80% of people have T-cell cross-reactivity to this coronavirusJohn Lee - Studies show that 40% to 80% of people have T-cell cross-reactivity to this coronavirusGabriela Gomes - Herd immunity thresholds for SARS-CoV-2Gabriela Gomes - Herd immunity thresholds for SARS-CoV-2Sunetra Gupta - Three Myths: 1 - We can keep it outSunetra Gupta - Three Myths: 1 - We can keep it outSunetra Gupta - Something that is becoming a scientific fact: Pre-existing resistance to COVID-19Sunetra Gupta - Something that is becoming a scientific fact: Pre-existing resistance to COVID-19A NEW STUDY  On Vitamin DA NEW STUDY On Vitamin DCOVID-19 Update 18: When are patients really infectious?COVID-19 Update 18: When are patients really infectious?Michael Yeadon - If the false positive rate is higher than the prevalence you cannot use the assayMichael Yeadon - If the false positive rate is higher than the prevalence you cannot use the assayAndrew Neil interviews Anders Tegnell - a second wave and what Sweden got right | SpectatorTVAndrew Neil interviews Anders Tegnell - a second wave and what Sweden got right | SpectatorTVThe Significance of Early Ct’s - Ask TaqMan #35The Significance of Early Ct’s - Ask TaqMan #35Herd Immunity and Effects: What if Some Don't Cooperate with COVID 19 Rapid Testing? with Dr. MinaHerd Immunity and Effects: What if Some Don't Cooperate with COVID 19 Rapid Testing? with Dr. MinaDavid Livermore - Lockdowns aren't the way out: "It is merely kicking the can down the road"David Livermore - Lockdowns aren't the way out: "It is merely kicking the can down the road"Positive PCR Test. Is It Really Positive?Positive PCR Test. Is It Really Positive?Pandemic, Child cases and lowering fatality ratesPandemic, Child cases and lowering fatality ratesNew Approaches to Covid-19: Rapid Testing, Herd Immunity, and the Role of NarrativeNew Approaches to Covid-19: Rapid Testing, Herd Immunity, and the Role of Narrative
Яндекс.Метрика